echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > National collection and expansion of the ground for half a year three varieties of the lowest degree of completion! China Sea, AstraZeneca...

    National collection and expansion of the ground for half a year three varieties of the lowest degree of completion! China Sea, AstraZeneca...

    • Last Update: 2020-08-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    PemeQusa, Gifitini, Fusimpuri set the lowest progress! Recently, Jiangxi Province reported on the implementation of the state-organized drug centralized procurement and use of the work, since March, Jiangxi Province every month will be published the first batch of 4 plus 7 national expansion of the province's implementation.
    the first batch of 4 plus 7 national expansion in the end of 2019 began to implement, the current landing has been six months, the second batch of national collection landing soon and some varieties affected by the epidemic, so that the first batch of 4 plus 7 expansion of the situation, perhaps more representative of the 4-7 model extended to the national scope, the actual implementation of the situation.
    01 the progress of each variety is very different since March this year, Jiangxi Province has been three months in a row to inform the first batch of 25 varieties of 31 standards of the landing situation.
    and looking at the six months of progress, we find that there is a huge difference in the pace of collection between different varieties.
    first of all, the completion of the varieties of Permeycise, Gifitini, Fusinpuri, Oripine ping is relatively low compared to other products, as of May 31, that is, five months and ten days, 50mg specification of the Pemequalse completion progress of 55.34%, is the lowest completion schedule, However, relative to less than 50% of the time, this progress is still reasonable, and, the proportion of the selected varieties accounted for the total quantity of all drugs purchased under the same rules is 95.90%, which belongs to the top three levels in 31 rules, which shows that the province's medical institutions are still in accordance with the requirements of centralized procurement landing work, the proportion of selected varieties in the market is still relatively high.
    PeiMeiqusai's supplier in Jiangxi is Sichuan Huiyu Pharmaceuticals, while the selected companies of Jifeitini, Fusinpuri and O'Niping are AstraZeneca, Huahai and Haussen.
    second, Jiangxi Province has 9 varieties in a quarter to complete the total amount of the whole year, and in the fourth and fifth months of the collection, this figure reached 17 and 21, respectively, it can be seen that most products completed faster, and can achieve much more than the medical institutions reported the purchase volume.
    , as of May 31 to complete 2 times the purchase volume of five products, respectively, left B. Rasitan, Imatini, right Metomidin, chloratan (50mg), Tinofuwe, of which the left Eablytan completion is the highest, close to 600%, this variety in Jiangxi supplier sending Zhejiang Jingxin Pharmaceuticals.
    in general, as of May 31, Jiangxi Province 31 rules of the province's total procurement volume of the agreed total amount of 118.56 percent, 21 rules completed the province's agreed procurement quantity, 6 standards completed 75%, 4 standards completed 50%, many enterprises will be far larger than the agreed purchase volume of the market, of course, this is related to the accuracy of the original medical institutions reported.
    and the second batch of national collection results from April 11 in Jiangxi Province, as of May 31, in 51 days, 36 rules of the province's total procurement volume accounted for 57.08 percent of the total purchase, 4 product regulations completed the province's agreed procurement quantity, 11 rules to complete the progress of more than 50%.
    , the highest completion progress was 696.92% of Abitron 0.25g and the lowest was 1.99% of Bisorol 2.5mg.
    and from the situation of the proportion of drugs, the total quantity of 36 product regulations of the province's procurement accounted for 84.88 percent of the total quantity of all drugs under the same regulations;
    Amoxilin in Jiangxi's selected manufacturers for North China Pharmaceuticals, the relatively low proportion of drugs may be related to many enterprises with Amoxilin batch number, pharmaceutical intelligence network data show that the variety of domestic a total of 32 approval information, and Alysson Tan film competition pattern is relatively good, only GSK, Huahai, Howson and Zhengda Sunny four have approval, and domestic manufacturers approved in two years. what is the fate of the unselected breed s
    02? Although the first two rounds of national collection completed the progress exceeded expectations, but in the next national collection, the balance retention policy will greatly affect the medical institutions reported, the industry believes that the past reported less than expected, data distortion in the future or will not be.
    since the 2018 4-7 pilot to two rounds of national collection, the policy of national organization drug collection has been evolving, but the previous case of the resulting products will more or less provide a certain precedent for late inclusion in the collection of varieties for reference.
    But how much of a reference to these precedents is if the industry's health-care balance retention policy is in place? At present, some provinces are adding some of the non-selected drugs hanging network, June 30, Henan Province on Ntikawe, including 109 drugs have been added to the network, July 1, Qinghai Province issued a non-selected drug application hanging network and price adjustment notice.
    , as in most provinces, Qinghai is no longer open to more than three varieties that have been evaluated.
    for the eligible unselected varieties, is still to encourage the state to centralize the procurement of non-selected enterprises in Qinghai Province at the national price of the secondary price in the province to buy;
    and the above-mentioned policy of retaining the health insurance balance, or will greatly change the fate of the unselected varieties.
    the core of this policy is to collect the difference between the cost of drugs after the price reduction and the budget fund paid by medical insurance, will be returned as part of the incentive to public medical institutions, the specific retention ratio by the co-ordination area according to the assessment results of fixed-point medical institutions.
    this will greatly affect the proportion of selected and unselected varieties used by medical institutions.
    the specific assessment content and the national collection and procurement agreement procurement volume, priority procurement, timely settlement, as well as the control of fees, truthfully reported procurement volume and other circumstances linked.
    fixed-point medical institutions that fail the examination shall not pay the collected balance to retain funds.
    Does this mean that the unselected variety is completely out of the market? Analysts believe that for some of the original research varieties and well-known varieties, especially patients with long-term drug use of the slow-disease varieties, after many years of market education and clinical practice, whether in the doctors or patient groups have a higher visibility and recognition, such products still have a market.
    in the previous collection in the determination of medical insurance payment standards also give such varieties 2-3 years of adjustment period, these varieties after a certain degree of price reduction may improve accessibility and coverage.
    in addition, from the terminal point of view, there is a view that in different levels of hospitals, the fate of non-selected varieties will be different, in large-scale triple-A hospitals, due to the large amount of dosage, the balance of many, so in addition to the original research of the unselected varieties of the opportunity is slim, and in the second and third terminal, whether the balance is large enough, it is not good to say that medical institutions in the selection of drugs there is still uncertainty.
    and from the point of view of product decline, analysts believe that medical institutions will undoubtedly be more inclined to choose products that have achieved significant price cuts, especially in the large budget of medical institutions and large price reduction products.
    at present, the third round of national collection is in the reporting stage, because this time the balance retention policy breaks through the logic of the past, so for pharmaceutical enterprises, according to this policy needs to carefully assess their products and decline, and for medical institutions, the balance retention policy is like a tight spell, gradually pull it and the direction of health insurance to the same position.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.